{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T17:35:16Z","timestamp":1762018516218,"version":"3.37.3"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1124\/dmd.123.001564","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T21:30:21Z","timestamp":1702416621000},"page":"236-241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs"],"prefix":"10.1016","volume":"52","author":[{"given":"Renmeng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn M.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard P.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raju","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-333X","authenticated-orcid":false,"given":"Yurong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001564_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2165\/00003088-197803020-00002","article-title":"Clinical pharmacokinetics of rifampicin","volume":"3","author":"Acocella","year":"1978","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001564_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0031-6989(78)80021-6","article-title":"Multicompartmental analysis of serum, urine and bile concentrations of rifampicin and desacetyl-rifampicin in subjects treated for one week","volume":"10","author":"Acocella","year":"1978","journal-title":"Pharmacol Res Commun"},{"key":"10.1124\/dmd.123.001564_bib3","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/psp4.12457","article-title":"Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction","volume":"8","author":"Asaumi","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001564_bib4","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/psp4.12275","article-title":"Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A\/2C9 Induction and OATP Inhibition Effects","volume":"7","author":"Asaumi","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001564_bib5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s002280050420","article-title":"The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin","volume":"54","author":"Backman","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001564_bib6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/00498254.2015.1085111","article-title":"Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III","volume":"46","author":"Bednarczyk","year":"2016","journal-title":"Xenobiotica"},{"issue":"Suppl 9","key":"10.1124\/dmd.123.001564_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1289\/ehp.94102s9101","article-title":"Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies","volume":"102","author":"Strolin Benedetti","year":"1994","journal-title":"Environ Health Perspect"},{"key":"10.1124\/dmd.123.001564_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-0711-5-3","article-title":"Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor","volume":"5","author":"Chen","year":"2006","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1124\/dmd.123.001564_bib9","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/cpt.1216","article-title":"Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium","volume":"104","author":"Chu","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001564_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","article-title":"4\u03b2-Hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans","volume":"71","author":"Diczfalusy","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001564_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.116.074476","article-title":"Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome","volume":"45","author":"Dong","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib12","doi-asserted-by":"crossref","first-page":"12565","DOI":"10.1038\/s41598-020-69228-z","article-title":"Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics","volume":"10","author":"Dyavar","year":"2020","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.123.001564_bib13","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0002-9440(10)64794-3","article-title":"The effect of rifampin treatment on intestinal expression of human MRP transporters","volume":"157","author":"Fromm","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1124\/dmd.123.001564_bib14a","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.386","article-title":"Rifampin modulation of xeno- and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes","volume":"6","author":"Gufford","year":"2018","journal-title":"Pharmacol Res Perspect"},{"key":"10.1124\/dmd.123.001564_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cbpc.2010.01.005","article-title":"Cloning\/characterization of the canine organic anion transporting polypeptide 1b4 (Oatp1b4) and classification of the canine OATP\/SLCO members","volume":"151","author":"Gui","year":"2010","journal-title":"Comp Biochem Physiol C Toxicol Pharmacol"},{"key":"10.1124\/dmd.123.001564_bib16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/clpt.2008.132","article-title":"Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4\u03b2-hydroxycholesterol","volume":"84","author":"Kanebratt","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001564_bib17","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1021\/jm300212s","article-title":"Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions","volume":"55","author":"Karlgren","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.123.001564_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1124\/dmd.109.029637","article-title":"Evaluation of cynomolgus monkey pregnane X receptor, primary hepatocyte, and in vivo pharmacokinetic changes in predicting human CYP3A4 induction","volume":"38","author":"Kim","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib19","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40262-018-0648-3","article-title":"Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions","volume":"57","author":"Kunze","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001564_bib20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1124\/dmd.122.001012","article-title":"The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition-Progress from 2016 to 2023","volume":"51","author":"Lai","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2020.11.003","article-title":"The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects","volume":"36","author":"Lee","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.123.001564_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1124\/dmd.114.057224","article-title":"4\u03b2-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys","volume":"42","author":"Li","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s13238-015-0148-2","article-title":"The physiological role of drug transporters","volume":"6","author":"Liang","year":"2015","journal-title":"Protein Cell"},{"key":"10.1124\/dmd.123.001564_bib24","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/rcm.2987","article-title":"Determination of midazolam and its hydroxy metabolites in human plasma and oral fluid by liquid chromatography\/electrospray ionization ion trap tandem mass spectrometry","volume":"21","author":"Link","year":"2007","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1124\/dmd.123.001564_bib25","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1124\/dmd.123.001277","article-title":"Characterization of Elimination Pathways and the Feasibility of Endogenous Metabolites as Biomarkers of Organic Anion Transporter 1\/3 Inhibition in Cynomolgus Monkeys","volume":"51","author":"Liu","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib26","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1124\/dmd.113.054361","article-title":"Endogenous 4\u03b2-hydroxycholesterol-to-cholesterol ratio is not a validated biomarker for the assessment of CYP3A activity","volume":"41","author":"Ma","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2174\/1389200218666170724110818","article-title":"Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes","volume":"18","author":"Mariappan","year":"2017","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.123.001564_bib28","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.bcp.2011.08.003","article-title":"Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine","volume":"82","author":"Nakajima","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.123.001564_bib29","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2967\/jnumed.112.108233","article-title":"In vivo visualization and quantification of (Disturbed) Oatp-mediated hepatic uptake and Mrp2-mediated biliary excretion of 99mTc-mebrofenin in mice","volume":"54","author":"Neyt","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.123.001564_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/cpt.1818","article-title":"The Systems Biology of Drug Metabolizing Enzymes and Transporters: Relevance to Quantitative Systems Pharmacology","volume":"108","author":"Nigam","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001564_bib31","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1124\/dmd.119.088922","article-title":"Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo","volume":"47","author":"Niu","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1208\/s12248-013-9470-x","article-title":"Drug-drug interaction studies: regulatory guidance and an industry perspective","volume":"15","author":"Prueksaritanont","year":"2013","journal-title":"AAPS J"},{"key":"10.1124\/dmd.123.001564_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/clpt.2010.271","article-title":"Rifampin\u2019s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design","volume":"89","author":"Reitman","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001564_bib34","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cpt.2510","article-title":"Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics","volume":"111","author":"Robbins","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001564_bib35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/dmd.119.089615","article-title":"Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?","volume":"48","author":"Rodrigues","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib36","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/cts.12774","article-title":"Effect of Rifampin-Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel","volume":"13","author":"Schilling","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.123.001564_bib37","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1124\/dmd.110.035295","article-title":"Metabolism of 1\u2032- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7","volume":"38","author":"Seo","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib38","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1124\/dmd.118.081125","article-title":"Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition","volume":"46","author":"Shen","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.116.232066","article-title":"Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species","volume":"357","author":"Shen","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.123.001564_bib40","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1124\/dmd.117.077586","article-title":"Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys","volume":"46","author":"Shen","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib41","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/dmd.32.1.140","article-title":"An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes","volume":"32","author":"Soars","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib42","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1016\/j.xphs.2019.03.021","article-title":"Effect of Rifampicin on the Plasma Concentrations of Bile Acid-O-Sulfates in Monkeys and Human Liver-Transplanted Chimeric Mice With or Without Bile Flow Diversion","volume":"108","author":"Takehara","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.123.001564_bib43","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/dmd.114.061580","article-title":"Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics","volume":"43","author":"Wang","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib44","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1124\/dmd.111.041814","article-title":"Hepatic uptake in the dog: comparison of uptake in hepatocytes and human embryonic kidney cells expressing dog organic anion-transporting polypeptide 1B4","volume":"39","author":"Wilby","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001564_bib45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.livres.2019.08.001","article-title":"Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism","volume":"3","author":"Wright","year":"2019","journal-title":"Liver Res"},{"key":"10.1124\/dmd.123.001564_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/clpt.2008.186","article-title":"Elucidating rifampin\u2019s inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite","volume":"85","author":"Zheng","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001564_bib47","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0006-2952(03)00189-8","article-title":"Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid","volume":"65","author":"Zhou","year":"2003","journal-title":"Biochem Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624011383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624011383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:16:08Z","timestamp":1739956568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624011383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0090955624011383"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001564","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}